Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma (STERIMGLI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02866747
Recruitment Status : Suspended (Interim analysis)
First Posted : August 15, 2016
Last Update Posted : August 9, 2019
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Institut Claudius Regaud

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : July 2020